Introduction
============

Incidence of nasopharyngeal carcinoma (NPC) in southern China is high and NPC is a common head and neck malignancy ([@b1-ol-0-0-9650]). The etiology of the disease varies, and EB virus infection, genetic and environmental factors all contribute to its occurrence ([@b2-ol-0-0-9650]). Incidence rate of NPC has reached 10/300,000 ([@b3-ol-0-0-9650]). More than half of the patients are in advanced stages at the time of diagnosis, and \~1/3 of patients have a survival period of \<5 years ([@b4-ol-0-0-9650]). NPC has the characteristics of rapid growth, high degree of malignancy, and is prone to early metastasis. Distant metastasis is the main cause of death after radiotherapy, and \~60--70% of patients are diagnosed with distant metastases ([@b5-ol-0-0-9650]). Tumor metastasis is the detachment of the tumor cells from their primary site to traffic through blood vessels or lymphatic vessels, reach distant positions and form tumors of the same nature. In this process, low level of E-cadherin reduces intercellular adhesion, induces epithelial-mesenchymal transition, and promotes invasion and metastasis of tumor cells ([@b6-ol-0-0-9650]).

MicroRNA is a group of short single-stranded RNAs identified in eukaryotic cells with pivotal roles in the regulation of post-transcriptional gene processing ([@b7-ol-0-0-9650]). Increasing number of studies have shown that microRNA plays an important role in regulating tumor invasion and metastasis ([@b8-ol-0-0-9650]). Studies have also shown that microRNA-141 is upregulated in endometrial and colorectal cancers, and the higher the expression, the worse the prognosis is ([@b9-ol-0-0-9650],[@b10-ol-0-0-9650]). In addition, some studies have suggested that microRNA-141 is highly expressed in NPC, but some other studies have reported that microRNA-141 expression is not observed in NPC and adjacent normal tissues ([@b11-ol-0-0-9650]). At present, the functional role of microRNA-183 and microRNA-141 in NPC is still controversial. This study explored the influence of microRNA-183 and microRNA-141 on prognosis of patients with NPC with an expectation of providing guidance for the diagnosis, treatment and prognosis of NPC and other tumors.

Materials and methods
=====================

### General information

A total of 317 NPC patients admitted to Zhengzhou Central Hospital Affiliated to Zhengzhou University (Zhengzhou, China) between January 2010 and March 2016 were selected for this research. Patients included 238 males and 79 females. All patients underwent routine nasopharynx and neck MRI, chest CT, abdominal CT, and bone scans to determine the recurrence and distant metastases. Inclusion criteria: i) age ≥18 years, ≤65 years; ⅱ) patients who had received no radiotherapy or chemotherapy prior to treatment; ⅲ) there were no other malignant tumors or other diseases severely affecting survival; and ⅳ) there were no immediate relatives among the patients. Precautionary and lactating women were excluded. All patients or their relatives signed an informed consent. The study was approved by the Ethics Committee of Zhengzhou Central Hospital Affiliated to Zhengzhou University.

### Main reagents and instruments

TRIzol RNA extraction kit and miRNA first-strand cDNA synthesis kit (both from Sangon Biotech Co., Ltd., Shanghai, China); SYBR^®^ PrimeScript™ miRNA RT-PCR kit (Takara Bio, Inc., Otsu, Japan); NanoDrop 2000 (Thermo Fisher Scientific, Inc., Waltham, MA, USA); CFX96 fluorescence quantitative PCR instrument (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

### Specimen collection and RNA extraction

NPC tumor and adjacent healthy tissues were collected from NPC patients and were stored in a refrigerator at −80°C. Total RNA was extracted from the tissues by using TRIzol RNA extraction kit. The specific extraction steps were as follows: TRIzol was added to lysate cells, followed by centrifugation at 4°C (12,300 × g) for 10 min; supernatant was transferred to a new RNase-free tube, and equal volume of chloroform was added, followed by centrifugation at 4°C (12,300 × g) for 10 min; supernatant was transferred to a new RNase-free tube, and equal volume of isopropanol was added and kept at room temperature for 1 h, followed by centrifugation at 4°C (12,300 × g) for 10 min; supernatant was discarded, and the pellet was washed twice with 75% ethanol; after air dry, DEPC water was added. NanoDrop 2000 was used to test RNA quality and concentration. RNA with a A260/280 ratio \>1.8 was subjected to 1.5% agarose gel electrophoresis to check RNA integrity.

### First-strand cDNA synthesis

First-strand cDNA was synthesized according to the instructions of cDNA first strand synthesis kit. The reaction system consisted of 1 µl of 2.5 U/µl poly(A) polymerase, 1 µl of RTase Mix, 5 µl of 5X PAP/RT buffer, 2 µg of total RNA, and RNase free dH~2~O was added to reach a final volume of 25 µl. Reaction conditions: 37°C for 1 h and 85°C for 5 min.

### Detection of microRNA-183 and microRNA-141 expression in lesion and adjacent tissues of patients by reverse transcription-quantitative PCR (RT-qPCR)

Synthesized cDNA was used as template and U6 as an endogenous control. MicroRNA-183 and microRNA-141 expression levels were detected by RT-qPCR. Reaction system: 10 µl of SYBR-Green Master Mix, 0.5 µl of upstream and downstream primers, 1 µl of cDNA, and ddH~2~O was added to reach a final volume of 20 µl. MicroRNA-141-F and microRNA-183-F were used as upstream primers, and Uni-miR qPCR Primer in SYBR^®^ PrimeScript™ miRNA RT-PCR kit was used as downstream primer ([Table I](#tI-ol-0-0-9650){ref-type="table"}). The RT-qPCR reaction conditions were: 95°C for 3 min, followed by 40 cycles of 95°C for 30 sec and 58°C for 1 min. Data were processed using 2^−ΔΔCq^ method ([@b12-ol-0-0-9650]).

### Statistical analysis

SPSS 17.0 (Beijing Xinmei Jiahong Technology Co., Ltd., Beijing, China) was used for statistical analysis. Measurement data were expressed as mean ± SD, and t-test was used for the comparison between two groups. Chi-square test was used for comparison of enumeration data. Kaplan-Meier test was used for the survival analysis followed by a long-rank test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### General clinical data

A total of 317 NPC patients admitted to Zhengzhou Central Hospital Affiliated to Zhengzhou University from January 2010 to March 2015 were included. The patients were 238 males and 79 females, aging from 18 to 65 years, with a median age of 45 years. A total of 157 cases presented distant metastasis, 136 cases had no distant metastasis, and distant metastasis was unclear in 24 cases. In addition, 172 patients had a disease-free survival (DFS) ≥3 years, and 145 patients had DFS \<3 years. Tumors were confined to the nasopharyngeal area or had infiltrated the pharyngeal soft tissue in 56 cases. Lymph node metastasis occurred in 308 patients ([Table II](#tII-ol-0-0-9650){ref-type="table"}). The 1-, 2-, and 3-year survival rates of the 317 patients were 82.6% (262), 64.4% (204), and 54.3% (172), respectively.

### Analysis of the expression levels of microRNA-183 and microRNA-141

The expression of microRNA-183 and microRNA-141 was detected by RT-qPCR. The results showed that the expression levels of microRNA-183 and microRNA-141 in lesion tissues were significantly higher than those in adjacent tissues (p\<0.05, [Table III](#tIII-ol-0-0-9650){ref-type="table"}). Patients with distant metastases had significantly higher expression levels of microRNA-183 and microRNA-141 (3.85±0.23 and 3.95±0.13) than patients without distant metastasis (1.35±0.15 and 1.52±0.11; p\<0.01, [Fig. 1](#f1-ol-0-0-9650){ref-type="fig"}). Patients with DFS \<3 years showed significantly higher levels of microRNA-183 and microRNA-141 (3.73±0.18 and 3.50±0.08) than patients with DFS ≥3 years (1.51±0.10 and 1.18±0.05; p\<0.01, [Fig. 2](#f2-ol-0-0-9650){ref-type="fig"}).

### Relationship between microRNA-183 and microRNA-141 and prognosis

The relative expression levels of microRNA-183 and microRNA-141 in the lesion tissue of NPC patients were 2.78±0.35 and 2.52±0.43, respectively. With the average value as threshold, patients were divided into high and low expression groups. There were 163 cases with high expression of microRNA-183, 154 cases with low expression of microRNA-183, 161 cases with high expression of microRNA-141, and 156 cases with low expression of microRNA-141. After 3 years of follow-up for these patients, 163 patients with high microRNA-183 expression had recurrence and the total number of deaths was 124 (76.1%), and 154 patients with low microRNA-183 expression had recurrence and the total number of deaths was 21 (13.6%). A total of 161 patients with high expression of microRNA-141 had recurrence and the total number of deaths was 128 (79.5%), and 156 patients with low expression of microRNA-141 had recurrence and the total number of deaths was 17 (10.9%). The recurrence and mortality rates of high and low expression groups of microRNA-183 and microRNA-141 were significantly different from each other (χ^2^ was 124.382 and 150.257, respectively; p\<0.01), suggesting that the high expression of microRNA-183 and microRNA-141 was associated with poor prognosis ([Figs. 3](#f3-ol-0-0-9650){ref-type="fig"} and [4](#f4-ol-0-0-9650){ref-type="fig"}).

Discussion
==========

The occurrence and development process of NPC is complex, and distant metastasis is an important cause of death in NPC patients ([@b13-ol-0-0-9650]). Therefore, it is particularly important to explore the relevant molecular mechanisms of NPC distant metastasis.

MicroRNA plays an important role in the invasion of tumor cells. Recent studies have found that microRNA exerts the dual role of oncogenes and tumor suppressor gene in the development of tumors ([@b14-ol-0-0-9650]).

MicroRNA-183 can inhibit metastasis of cancer cells by inhibiting ezrin protein in lung ([@b15-ol-0-0-9650]) and breast cancer ([@b16-ol-0-0-9650]). In addition, it can also inhibit migration of lung cancer cells by downregulating WISP2 protein or upregulating the expression of S100P protein ([@b17-ol-0-0-9650]). MicroRNA-183 inhibits the expression of cell death factor 4 (PDCD4) in liver cancer and inhibits cell apoptosis ([@b18-ol-0-0-9650]). MicroRNA-183 inhibits the metastasis of colon cancer cells by inhibiting the expression of EGR1 and PTEN ([@b19-ol-0-0-9650]). In addition, the role of microRNA-183 in tumors is tissue-specific. MicroRNA-183 can play a tumor suppressive role and can also promote tumor invasion and migration in different cancer cells ([@b20-ol-0-0-9650]). In this study it was found that the expression level of microRNA-183 in patients with distant metastasis is significantly higher than that in patients without distant metastasis (p\<0.01), suggesting that the expression level of microRNA-183 can be used to predict distant metastasis in NPC patients. When distant metastasis occurs, the expression of microRNA-183 increases, and microRNA-183 plays an important role in promoting the metastasis of tumor cells in NPC. Sarver *et al* ([@b21-ol-0-0-9650]) have found that the upregulation of microRNA-183 in colon cancer plays an important role in promoting the development of cancer. In the present study, it was found that the expression level of microRNA-183 in patients with DFS \<3 years is significantly higher than that in patients with DFS ≥3 years (p\<0.01), suggesting that microRNA-183 expression level is related to postoperative survival. At the end of the follow-up, recurrence and mortality were significantly higher in the microRNA-183 high expression group than in the low expression group, suggesting that high microRNA-183 expression is closely related to poor prognosis.

MicroRNA-141 is a member of microRNA-200 family. Xia *et al* ([@b22-ol-0-0-9650]) have found that the expression level of microRNA-141 in NPC cell lines with low differentiation is higher than that in highly differentiated NPC cell lines. It was considered that the increase of microRNA-141 expression attributes to NPC occurrence at early stage. In addition, microRNA-141 expression pattern is extremely different in different tumor cells, such as high expression in ovarian cancer ([@b23-ol-0-0-9650]), and low expression in hepatoma cells ([@b24-ol-0-0-9650]). In this study, the expression level of microRNA-141 was significantly higher in patients with distant metastasis than in patients without distant metastasis (p\<0.01). Ahmed *et al* ([@b25-ol-0-0-9650]) have found that the appearance of lymph node and distant metastasis is accompanied by the increased expression level of microRNA-141, which is consistent with the findings in this study. The expression level of microRNA-141 in patients with DFS \<3 years was significantly higher than that in patients with DFS ≥3 years (p\<0.01). Furthermore, recurrence and mortality of patients with high expression of microRNA-141 were also significantly higher than those of patients with low expression, suggesting that increased expression of microRNA-141 predicts distant metastasis and shortened DFS, and leads to poor prognosis.

In conclusion, microRNA-183 and microRNA-141 can be used as markers for the prediction of distant metastasis of NPC, and have a reference value for the prognosis of NPC. The specific molecular mechanism of microRNA-183 and microRNA-141 in the occurrence and development of NPC remains to be further studied.
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###### 

Primer sequences.

  Primers (5′-3′)       Sequences
  --------------------- ----------------------------------
  Uni-miR qPCR primer   Takara kit
  MicroRNA-141-F        CGTAACACTGTCTGGTAAAGATGGA
  MicroRNA-183-F        ACACTCCAGCTGGGTATGGCACTGGTAGAATT
  U6-F                  CTCGCTTCGGCAGCACA
  U6-R                  AACGCTTCACGAATTTGCGT

###### 

General clinical data of 317 NPC patients.

  Variable                   n (%)
  -------------------------- ------------
  Age (years)                
    ≥45                      156 (49.2)
    \<45                     161 (50.8)
  Sex                        
    Male                     238 (75.1)
    Female                   79 (24.9)
  Distant metastasis         
    Unclear                  24 (7.6)
    Non-distant metastasis   136 (42.9)
    Distant metastasis       157 (49.5)
  DFS (years)                
    ≥3                       172 (54.3)
    \<3                      145 (45.7)
  T period                   
    T1                       13 (4.1)
    T2                       43 (13.6)
    T3                       166 (52.4)
    T4                       95 (30.0)
  N stages                   
    N0                       9 (2.8)
    N1                       91 (28.7)
    N2                       168 (53.0)
    N3                       49 (15.5)

NPC, nasopharyngeal carcinoma; DFS, disease-free survival.

###### 

Expression of microRNA-183 and microRNA-141 in lesions and adjacent tissues (mean ± SD).

  Groups         Lesions     Adjacent tissues   t       P-value
  -------------- ----------- ------------------ ------- ---------
  microRNA-183   3.11±0.09   1.21±0.10          4.771   0.041
  microRNA-141   2.98±0.12   1.13±0.08          8.215   0.014
